Company: ARTL
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0001640334-25-000335
Chunk: 519

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 2
Chunk 519
---
000 shares authorized and        3,281,032 and 3,188,959 shares issued and outstanding as of December 31, 2024, and 2023, respectively  3   3 Additional paid-in capital  53,192   52,262 Accumulated deficit  (50,136)  (40,310)Accumulated other comprehensive loss  (202)  (203)TOTAL STOCKHOLDERS' EQUITY  2,857   11,752          TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $4,698  $13,043 

The accompanying notes are an integral part of these audited consolidated financial statements.

 F-3Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

  Year ended   December 31,   2024  2023        OPERATING EXPENSES      General and administrative $4,115  $4,234 Research and development  5,993   5,696 Total Operating Expenses  10,108   9,930          Loss from Operations  (10,108)  (9,930)         OTHER INCOME        Net change in fair value of trading marketable securities  282   641 Total other income  282   641          Provision for income taxes  -   -          NET LOSS $(9,826) $(9,289)         OTHER COMPREHENSIVE INCOME        Foreign currency translation adjustments  1   51 Total Other Comprehensive Income  1   51          TOTAL COMPREHENSIVE LOSS $(9,825) $(9,238)         Basic and Diluted Loss per Common Share $(3.05) $(3.14)         Basic and Diluted Weighted Average Common Shares Outstanding  3,223   2,960 

The accompanying notes are an integral part of these audited consolidated financial statements.

 F-4Table of Contents

ARTELO BIOSCIENCES, INC.

Consolidated Statements of Stockholders’ Equity

(In thousands)

     Additional     Accumulated Other       Common stock  paid-in